Intest opened lower at $13.99, compared with its previous close of $14.49. In the last trading session, the stock traded between $13.99 and $15.40. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Intest is now worth
$ 96.29
Resulting in a loss of
$ 3.71 (3.71%)
Invest with $1
Note: Past profits do not guarantee future returns.
Adjusted EPS of $0.18 beat consensus estimate of $0.12 by 50%. Revenue of $35.069 million exceeded analyst estimate of $34.800 million. Net earnings swung to $1.9 million from a loss of $0.9 million YoY. Orders hit record $49.4 million, up 31% YoY and 71.2% QoQ.
6 days ago
5Oct
InTest Corp Q3FY26 Results: Orders hit record $50M, revenue at high end
InTest Corp reported record orders of $48 million to $50 million for Q3FY26, marking a 28% to 33% year-on-year increase. Revenue is projected at the high end of the $33 million to $35 million guidance range, reflecting over 30% YoY growth. Backlog expanded sequentially by 28% to 32% to reach $58 million to $60 million, driven by back-end semiconductor demand.
InTest Corp delivered a strong Q2 performance with EPS of $0.09 beating estimates by 80% and revenue rising 25.5% to $35.3 million. The results were driven by surging Auto/EV demand, leading to a 73.7% jump in adjusted EBITDA.
inTest projects Q3 sales of $33.000M-$35.000M, missing the $35.068M analyst estimate. The guidance highlights a revenue shortfall against consensus expectations for the quarter.
3mo ago
31Jul
inTest Q2 Results: Sales guidance raised to $35.000M vs $33.013M est
inTest upgrades Q2 preliminary sales guidance to $35.000 million, beating the $32.000 million-$34.000 million range and $33.013 million estimate. The revision highlights strong operational performance ahead of final results.
3mo ago
31Jul
InTest raises FY26 sales guidance to $135-140M vs $133.9M estimate
InTest Corporation raised its full-year 2026 revenue guidance to $135-140 million, exceeding the $133.911 million estimate, driven by strong Q2 revenue of $35 million. Despite the top-line beat, gross margins missed expectations at ~40% due to operational issues at Alfamation and supply chain disruptions, leading to a revised full-year margin outlook of ~43%.
